DNDi is a not-for-profit drug development initiative established in 2003 by four publicly-funded research organisations - Kenya Medical Research Institute, Indian Council for Medical Research, Oswaldo Cruz Foundation Brazil, Malaysian Ministry of Health; a private research institute, the Institut Pasteur; an international research organisation WHO's Tropical Diseases Research programme; and an international humanitarian organisation Médecins Sans Frontières.

DNDi aims to develop new, improved and field-relevant drugs for neglected diseases such as leishmaniasis, human African trypanosomiasis, and Chagas disease that afflict the very poor in developing countries. It will raise awareness of the urgent need to develop drugs for these diseases and use DNDi projects to strengthen existing capacity in disease-endemic countries.

Call to governments
Boost Innovation for Neglected Diseases

Provide significant and sustained support to bring essential new drugs, vaccines, and diagnostics to people suffering and dying from neglected diseases.
See also:
Visceral Leishmaniasis:
New Health Tools Are Needed
Extract from an article in the Public Library of Science Medicine PLoS Med 2{7}:e211.
Clinical Development:

Testing new drugs in patients.
Leishmaniasis Clinical Research Centre in Arba Minch, Ethiopia

In conducting clinical research in the disease-endemic countries, DNDi and its partners often face a lack of capacity...

Meet Prof Ahmed M El Hassan, Institute of Endemic Diseases, University of Khartoum

Prof El Hassan was a young research assistant in 1958 when he saw his first case of visceral leishmaniasis...

Published by Drugs for Neglected Diseases Initiative
1 Place St Gervais 1201 Geneva Switzerland
Editor: Jaya Banerji - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org